



# **Waiting Times for Suspected and Diagnosed Cancer Patients**

*2013-14 Annual Report*

# Waiting Times for Suspected and Diagnosed Cancer Patients

*2013-14 Annual Report*

Prepared by Jonathan Pearson, Scott Burgess, Paul McDonnell and Mark Svenson

© Crown copyright 2014

First published: 25<sup>th</sup> July 2014

Published to NHS England website, in electronic PDF format only.

<http://www.england.nhs.uk/statistics/statistical-work-areas/>

## Contents

<b>1</b>	<b>Summary .....</b>	<b>4</b>
<b>2</b>	<b>Introduction.....</b>	<b>5</b>
<b>3</b>	<b>Methodology .....</b>	<b>7</b>
<b>4</b>	<b>Provider-based statistics .....</b>	<b>8</b>
4.2	Two week wait .....	8
4.3	Two week wait for symptomatic breast patients.....	10
4.4	31-day waits for first treatment.....	11
4.5	31-day waits for subsequent treatments .....	13
4.6	62-day wait for first treatment following an urgent GP referral .....	16
4.7	62-day wait for first treatment following referral from a creening service .....	18
4.8	62-day wait for first treatment following a consultant decision to upgrade .....	19
<b>5</b>	<b>Colour Maps of Cancer Waiting Times .....</b>	<b>20</b>
	<b>Annex A Commissioner-based statistics.....</b>	<b>23</b>
	<b>Annex B Glossary of terms .....</b>	<b>24</b>

# 1 Summary

The overall performance for 2013-14, against the nine cancer standards, is set out below for the provider data set.

## 1.1 Two week waits

In 2013-14, the percentage of patients who were seen by a specialist within 14 days of being urgently referred for suspected cancer by their GP was 95.3%

In 2013-14, the percentage of patients who were seen by a specialist within 14 days of being urgently referred by their GP with exhibited breast symptoms (where cancer was not initially suspected) was 94.8%

## 1.2 31-day waits for first treatment for all cancers

In 2013-14, the percentage of patients receiving a first definitive treatment for cancer who began that treatment within 31 days was 98.3%

## 1.3 31-day waits for second or subsequent treatment for all cancers

In 2013-14, the percentage of patients receiving subsequent treatment for cancer where the treatment modality was surgery began that treatment within 31 days was 97.3%

In 2013-14, the percentage of patients receiving subsequent treatment for cancer where the treatment modality was an anti-cancer drug regimen began that treatment within 31 days was 99.7%

In 2013-14, the percentage of patients receiving subsequent treatment for cancer where the treatment modality was radiotherapy began that treatment within 31 days was 97.6%

## 1.4 62-day waits for all cancers

In 2013-14, the percentage of patients who received a first treatment for cancer within 62 days following an urgent GP referral for suspected cancer was 86.0%. By quarter performance was above the operational standard of 85% for the first three quarters of 2013-14 and below the standard in Q4.

In 2013-14, the percentage of patients who received a first treatment for cancer within 62 days following referral from a NHS cancer screening service was 94.7%

In 2013-14, the percentage of patients who received a first treatment for cancer within 62 days following a consultant decision to upgrade their priority was 92.4%

## 2 Introduction

2.1 This report presents a summary of the Statistics on Waiting Times for Suspected and Diagnosed Cancer Patients within the English NHS for the period 2013-14. These data are an aggregate version of those provider based quarterly statistics available on the NHS England website at:

<http://www.england.nhs.uk/statistics/category/statistics/provider-waiting-cancer/>.

There may be some discrepancies between the statistics contained within this report and the previous quarterly publications, owing to further efforts to clean the dataset and present a more accurate analysis since individual quarters were published.

2.1.1 In a review<sup>1</sup> of cancer waiting times standards conducted in the summer of 2010 by Professor Sir Mike Richards it was found that shorter waiting times can lead to earlier diagnosis, quicker treatment, a lower risk of complications, an enhanced patient experience and improved cancer outcomes. Shorter waiting times can also help to ease patient anxiety and improve experience. Improving Outcomes: A Strategy for Cancer (January 2011)<sup>2</sup>, confirmed that the cancer waiting time standards should be retained, consequently they were identified within the Operating Framework for the NHS in England for 2012-13<sup>3</sup>, Everyone Counts: Planning for Patients 2013/14<sup>4</sup> and Everyone Counts: Planning for Patients 2014/15 to 2018/19<sup>5</sup>.

2.2 These standards, as with all monitored waiting times standards, are not expected to be met in all cases by the NHS. At any one time, there will be a number of patients who are not available for treatment within a waiting time standard because: they elect to delay their treatment (patient choice), are unfit for their treatment, or it would be clinically inappropriate to treat them within the standard time. To account for this, NHS England has published 'operational standards' (performance thresholds)<sup>6</sup> that set the expected level of performance based on case mix, clinical requirements, potential numbers of patients unfit for treatment or electing to delay treatment (patient choice). The published operational standards for cancer waiting times are:

Waiting Times Measure	Operational Standard
Two week wait for all cancers	93%
Two week wait for symptomatic breast patients (where cancer was not initially suspected) <sup>7</sup>	93%
One Month (31-day) diagnosis to first treatment wait for all cancers	96%
31-day wait for second or subsequent treatment: anti-cancer drug treatments	98%
31-day wait for second or subsequent treatment: surgery	94%
31-day wait for second or subsequent treatment: radiotherapy treatments <sup>8</sup>	94%

<sup>1</sup>[https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/213787/dh\\_123395.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213787/dh_123395.pdf)

<sup>2</sup><https://www.gov.uk/government/publications/the-national-cancer-strategy>

<sup>3</sup><https://www.gov.uk/government/publications/the-operating-framework-for-the-nhs-in-england-2012-13>

<sup>4</sup><http://www.england.nhs.uk/wp-content/uploads/2012/12/everyonecounts-planning.pdf>

<sup>5</sup><http://www.england.nhs.uk/wp-content/uploads/2013/12/5yr-strat-plann-guid.pdf>

<sup>6</sup>[http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod\\_consum\\_dh/groups/dh\\_digitalassets/documents/digitalasset/dh\\_103431.pdf](http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_103431.pdf)

<sup>7</sup>Data for this standard was first published for Q4 2009-10

<sup>8</sup>Data for this standard was first published for Q4 2010-11.

Waiting Times Measure	Operational Standard
62-day wait for first treatment following an urgent GP referral for all cancers	85%
62-day wait for first treatment following referral from an NHS cancer screening service for all cancers	90%

2.3 The operational standards detailed above are based on 'all cancers' and take into account patient choice and other influencing factors. There will be variations between different tumour types. These variations are the result of differences in the types of tests a patient requires to confirm a diagnosis of cancer for each tumour group, the complexities of that treatment and the different choices those patients might make about their treatment.

2.4 The Government Statistical Service (GSS) statistician responsible for producing the data in this report is Mark Svenson, who can be contacted at the address or e-mail given below. If you have any feedback on the content of the publication, or would like any more information about the statistics themselves, please let us know at [cancer-waits@dh.gsi.gov.uk](mailto:cancer-waits@dh.gsi.gov.uk) or in writing at:

Cancer Waiting Times Team  
NHS England  
Room 8E28, Quarry House  
Quarry Hill  
Leeds  
LS2 7UE  
Great Britain

*Note: the last standard concerning a consultant decision to upgrade the priority of a patient does not have an operational standard, see para 47.1 of the review of cancer waits<sup>9</sup>.*

<sup>9</sup> [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/213787/dh\\_123395.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213787/dh_123395.pdf)

## 3 Methodology

- 3.1 These aggregate statistics are derived from patient records held on the Cancer Waiting Times Database (CWT-Db) in the format specified by the National Cancer Waiting Times Monitoring Dataset (NCWTMDS), full details of which can be found at: [http://www.datadictionary.nhs.uk/data\\_dictionary/messages/clinical\\_data\\_sets/data\\_sets/national\\_cancer\\_waiting\\_times\\_monitoring\\_data\\_set\\_fr.asp?shownav=1](http://www.datadictionary.nhs.uk/data_dictionary/messages/clinical_data_sets/data_sets/national_cancer_waiting_times_monitoring_data_set_fr.asp?shownav=1)
- 3.2 For the quarterly publication of Cancer Waiting Times statistics; following the 25<sup>th</sup> working day after the end of each quarter the CWT-Db provides NHS England with aggregated and anonymised extracts of the validated data on two-week wait periods, 31-day periods and 62-day referral to treatment periods for publication and reporting purposes. Prior to publication, NHS England analysts follow a set process to ensure that the published statistics are as accurate as possible. These statistics are either aggregated using the provider organisation details contained within the patient record or details of the registered primary care organisation, which can also be sourced from this patient record.
- 3.3 The national levels of activity and performance reported within this summary for commissioned services may differ from the equivalent provider based statistical summaries. This is because these commissioner-based statistics only include those patients who can be traced back to an English commissioner using their NHS Number. As a result, the national calculated performance levels may differ slightly between the two datasets. As these commissioner (Clinical Commissioning Groups) based statistics are derived from those data submitted by the providers of NHS cancer services, the provider based national statistics on waiting times for suspected and diagnosed cancer patients remain the most complete assessment of the performance of the English NHS.
- 3.4 It is not possible to alter any aggregate extract after it has been generated by the CWT-Db. This is because these data will have already been disseminated within the NHS as part of an automated process at the same time that the automated aggregate extract was generated. The CWT-Db will already have reported details of any activity to the NHS provider, the commissioning CCG and Area Teams, the local Area Team (if different) and the local cancer network. These automated reports cannot be altered to ensure consistency of information throughout the NHS and version control.
- 3.5 If an error is discovered after the automated processes of the CWT-Db have generated aggregate statistics for publication, the usual practice of the NHS England is to add a caveat or note explaining the inconsistency to the foot of the relevant data table within the quarterly publications.
- 3.6 Further documents outlining the methodology, including the revisions policy, and issues around security and confidentiality, can be found here: <http://www.england.nhs.uk/statistics/cancer-waiting-times/>

## 4 Provider-based statistics

4.1 The provider-based data include all patients treated by the English NHS, including those patients from Wales and those where a commissioning organisation could not be identified from their patient records. The provider-based set of statistics has been formally assessed for compliance with the Code of Practice for Official Statistics, and has been designated as National Statistics.

### 4.2 Two week wait for all cancer – (Operational Standard = 93%)

This standard covers patients seen by a specialist following an urgent GP referral for suspected cancer. The operational standard states that 93% of patients should be seen within 14 days of the referral.

Table 4.1: Activity and performance of the two week wait standard for all cancer.

Care Setting	Number of patients 2013-14	% seen within 14 days	
		2013-14	2012-13
All Care	1,361,345	95.3	95.5


Table 4.2: Activity and performance of the two week wait standard for different cancer sites in 2013/14. The two week wait operational standard was met for all suspected cancer sites.

Cancer Report Group	Total number of patients seen	% seen within 14 days
All Cancers	1,361,345	95.3
Suspected Acute Leukaemia	178	97.8
Suspected Brain/Central Nervous System Tumours	7,498	96.3
Suspected Breast Cancer	252,559	96.3
Suspected Children's Cancer	6,347	96.2
Suspected Gynaecological Cancer	124,468	95.9
Suspected Haematological Malignancies (Excluding Acute Leukaemia)	11,835	97.3
Suspected Head & Neck Cancer	126,314	95.8
Suspected Lower Gastrointestinal Cancer	209,265	94.9
Suspected Lung Cancer	52,460	97.1
Suspected Other Cancer	1,963	95.7
Suspected Sarcoma	6,316	96.2
Suspected Skin Cancer	247,444	94.9
Suspected Testicular Cancer	7,990	97.7
Suspected Upper Gastrointestinal Cancer	142,694	93.6
Suspected Urological Malignancies (Excluding Testicular Cancer)	164,013	94.9



**Waiting Times for Suspected and Diagnosed Cancer Patients  
2013-14 Annual Report**

Figure 4.1: The national quarterly activity and performance of urgent GP referrals for suspected cancer. Data from 2013/14 is compared against 2012/13.



**Summary**

The number of patients which are included in the two week wait standard continued to increase at a constant rate. A total increase of 11.6% occurred, compared with 2012/13. However, the performance remained above the standard and showed no significant overall increase or decrease in the trend.


### 4.3 Two week wait for symptomatic breast patients (where cancer was not initially suspected) – (Operational Standard = 93%)

This standard covers patients seen by a specialist following an urgent GP symptomatic breast referral where cancer was not initially suspected. The operational standard states that 93% of patients should be seen within 14 days of the referral.

Table 4.3: Activity and performance of the two week wait standard for symptomatic breast patients.

Care Setting	Number of patients 2013-14	% seen within 14 days	
		2013-14	2012-13
All Care	217,471	94.8	95.5

Figure 4.2: The national quarterly activity and performance for urgent GP referrals for breast symptoms (where cancer was not initially suspected). Data from 2013/14 is compared against 2012/13.



#### Summary

The number of patients referred onto the two week wait with breast symptoms (but where cancer is not suspected) increased most notably in Q4 of 2013/14. The performance shows large amounts of variation, compared with the previous year, but remains above the operational standard.

## 4.4 31-day waits for first treatment – (Operational Standard = 96%)

This standard covers patients starting a first definitive treatment for a new primary cancer. The operational standard states that 96% of patients should be seen within 31 days of the decision to treat date.


Table 4.4: Activity and performance of the one month wait standard for first cancer treatment.

Care Setting	Number of patients 2013-14	% seen within 31 days	
		2013-14	2012-13
All Care	267,783	98.3	98.4
Admitted Care	177,206	97.7	97.9
Non-Admitted Care	90,577	99.4	99.3

Table 4.5: Activity and performance of the one month wait standard for different cancer sites in 2013/14. The one month operational standard was met for all suspected cancer sites.


Cancer Report Group	Total number of patients seen	% seen within 31 days
All Cancers	267,783	98.3
Breast Cancer	44,652	99.2
Lower Gastrointestinal Cancer	28,833	98.5
Lung Cancer	29,562	98.7
Other Cancer	73,136	98.6
Skin Cancer	38,362	98.2
Urological Malignancies	53,238	96.6

Figure 4.3: The national quarterly activity and performance for the 31-day standard from a decision to treat to first treatment. Data from 2013/14 is compared against 2012/13.



**Waiting Times for Suspected and Diagnosed Cancer Patients  
2013-14 Annual Report**

Figure 4.4: The national quarterly activity and performance for the 31-day standard from a decision to treat to first treatment by cancer site.



**Summary**

The 31-day standard for first treatments saw an increase of 3.5% compared with 2012/13. Although a slight drop in performance is observed for the last two quarters, compared the previous year, the performance for this standard remains high.

No individual cancer site is seen to be increasing significantly more than the others. Urological cancers remain the largest individual cancer in terms of number of patients being treated. The performance of every individual cancer site remained above the standard for every quarter in 2013/14.


## 4.5 31-day waits for subsequent treatments for all cancers

This standard covers patients starting a subsequent treatment for a new primary cancer. The operational standard states that 98% of patients should be seen within 31 days of the decision to treat date where the treatment is an anti-cancer drug regime, 94% where the treatment is radiotherapy and 94% where the treatment is surgery.

Table 4.6: Activity and performance of the one month wait standard for subsequent cancer treatments.

Care Setting	Number of patients 2013-14	% seen within 31 days	
		2013-14	2012-13
<b>Surgery (Operational Standard = 94%)</b>			
All Care	55,839	97.3	97.4
Admitted Care	53,715	97.3	97.3
Non-Admitted Care	2,122	97.6	97.6
<b>Anti-Cancer Drug Regimen (Operational Standard = 98%)</b>			
All Care	87,464	99.7	99.7
Admitted Care	51,624	99.7	99.6
Non-Admitted Care	35,840	99.7	99.7
<b>Radiotherapy (Operational Standard = 94%)</b>			
All Care	96,300	97.6	98.0
Admitted Care	11,883	98.6	98.1
Non-Admitted Care	84,417	97.5	98.0

Figure 4.5: The national quarterly activity and performance for the 31-day standard from a decision to treat to a subsequent treatment where the treatment modality is surgery. Data from 2013/14 is compared against 2012/13.



**Waiting Times for Suspected and Diagnosed Cancer Patients  
2013-14 Annual Report**

Figure 4.6: The national quarterly activity and performance for the 31-day standard from a decision to treat to a subsequent treatment where the treatment modality is an anti-cancer drug regimen. Data from 2013/14 is compared against 2012/13.





Figure 4.7: The national quarterly activity and performance for the 31-day standard from a decision to treat to a subsequent treatment where the treatment modality is radiotherapy. Data from 2013/14 is compared against 2012/13.



**Waiting Times for Suspected and Diagnosed Cancer Patients  
2013-14 Annual Report**

**Summary**

The number of patients receiving a subsequent treatment saw only a slight increase. Radiotherapy was the only modality which saw a significant increase of approximately 5%. All three modalities remained high above their standards.

## 4.6 62-day wait for first treatment following an urgent GP referral – (Operational Standard = 85%)

This standard covers patients starting a first definitive treatment for a new primary cancer following an urgent GP referral for suspected cancer. The operational standard states that 85% of patients should be seen within 62 days of the referral date.

Table 4.7: Activity and performance of the two month wait standard for all cancer sites.

Care Setting	Number of patients 2013-14	% seen within 62 days	
		2013-14	2012-13
<b>All Care</b>	<b>125,275</b>	86.0	87.2
<b>Admitted Care</b>	<b>77,489</b>	85.3	86.8
<b>Non-Admitted Care</b>	<b>47,786</b>	87.0	88.0

Table 4.8: Activity and performance of the two month wait standard for different cancer sites in 2013/14.

Cancer Report Group	Total number of patients seen	% seen within 62 days
<b>All Cancers</b>	<b>125,275</b>	<b>86.0</b>
Breast Cancer	21,176	97.0
Lower Gastrointestinal Cancer	11,725	78.8
Lung Cancer	12,075	78.5
Other Cancer	30,120	80.9
Skin Cancer	20,767	96.7
Urological Malignancies	29,412	81.6

Figure 4.8: The national quarterly activity and performance for the 62-day standard from an urgent GP referral to a first definitive treatment. Data from 2013/14 is compared against 2012/13.







Figure 4.9: The national quarterly activity and performance for the 62-day standard from an urgent GP referral to a first definitive treatment by cancer site.



### Summary

The number of patients recorded under the 62-day standard increased by 6.2% from 2012/13 to 2013/14. No specific cancer site was responsible for this but rather a general increase across all cancers.

The performance saw a large drop in the third and fourth quarters leading to the standard being failed in Q4 2013/14. This is the first breach of the operational standards since they were introduced.


The performance for individual cancers showed that breast and skin cancers remained high and constant whereas urological and lung cancers had large decreases.

## 4.7 62-day wait for first treatment following referral from an NHS cancer screening service for all cancers – (Operational Standard = 90%)

Table 4.9 shows the performance of admitted verses non-admitted care and compare this to the data from 2012-13.

Care Setting	Number of patients 2013-14	% seen within 62 days	
		2013-14	2012-13
All Care	19,022	94.7	95.1
Admitted Care	17,622	95.1	95.4
Non-Admitted Care	1,400	90.0	91.2

Figure 4.10: The national quarterly activity and performance for the 62-day standard from a NHS cancer screening service referral to a first definitive treatment. Data from 2013/14 is compared against 2012/13.



### Summary


Patients recorded under the 62-day standard which were referred from a national screening programme saw an increase in patient numbers but maintained a high performance.

## 4.8 62-day wait for first treatment following a consultant decision to upgrade the case priority for all cancers – (Operational Standard = n/a)

Table 4.10 shows the performance of admitted verses non-admitted care and compare this to the data from 2012-13.

Care Setting	Number of patients 2013-14	% seen within 62 days	
		2013-14	2012-13
All Care	18,661	92.4	93.2
Admitted Care	11,741	92.5	93.0
Non-Admitted Care	6,920	92.1	93.6

Figure 4.11: The national quarterly activity and performance for the 62-day standard from a consultant upgrade to a first definitive treatment. Data from 2013/14 is compared against 2012/13.



### Summary

Patients recorded under the 62-day standard which were upgraded by a consultant onto the 62-day pathway saw a small increase in patient numbers. A small drop in the performance was also due to an overall downwards trend. No standard is set for this waiting time.

## 5 Colour Maps of Cancer Waiting Times


### 5.1 Two Week Waits from an Urgent GP Referral for 2013/14 (Operational Standard = 93%)

Provider % seen within 2 week

- ★ 93.5 % - 100 %
- ☆ 93 % - 93.49 %
- ★ 0 % - 92.99 %

CCG % seen within 2 weeks

- 93.5 % - 100 %
- 93 % - 93.49 %
- 0 % - 92.99 %




## 5.2 One Month Wait from a Decision to Treat to First Definitive Treatment for 2013/14 (Operational Standard = 96%)

Provider % seen within 31 Days - First Treatment

- ★ 96.5 % - 100 %
- ☆ 96 % - 96.49 %
- ☆ 0 % - 95.99 %

CCG % seen within 31 Days - First Treatment

- 96.5 % - 100%
- 96 % - 96.49 %
- 0 % - 95.99 %




### 5.3 Two Month Wait from an Urgent GPO Referral to First Definitive Treatment for 2013/14 (Operational Standard = 85%)

CCG % seen within 62 days - First Treatment

- 85.5 % - 100 %
- 85 % - 85.49 %
- 0 % - 84.99 %

Provider % seen within 62 days - First Treatment

- ★ 85.5 % - 100 %
- ★ 85 % - 85.49 %
- ★ 0 % - 84.99 %



## Annex A Commissioner-based statistics

A1 The overall performance for 2013-14, against the nine cancer standards is set out below for the commissioner data set.

A2 Please note: some of the commissioner-based figures may differ from the provider-based figures. This is because commissioner level data does not include those patients receiving treatment in English providers who are not registered at a GP Practice in England. The provider-based statistics remain the most complete assessment of NHS activity. The commissioner-based official statistics below are not designated as National Statistics as they have not yet been assessed by the UK Statistics Authority. NHS England's view is that these statistics are robust and have been produced to a suitable standard; they are included here to give extra context.

A4 **Two week waits**

In 2013-14, the percentage of patients who were seen by a specialist within 14 days of being urgently referred for suspected cancer by their GP was 95.3%

In 2013-14, the percentage of patients who were seen by a specialist within 14 days of being urgently referred by their GP with exhibited breast symptoms (where cancer was not initially suspected) was 94.8%

A5 **31-day waits for first treatment for all cancers**

In 2013-14, the percentage of patients receiving a first definitive treatment for cancer began that treatment within 31 days was 98.2%

A6 **31-day waits for second or subsequent treatment for all cancers**

In 2013-14, the percentage of patients receiving subsequent treatment for cancer where the treatment modality was surgery began that treatment within 31 days was 97.2%

In 2013-14, the percentage of patients receiving subsequent treatment for cancer where the treatment modality was an anti-cancer drug regimen began that treatment within 31 days was 99.8%

In 2013-14, the percentage of patients receiving subsequent treatment for cancer where the treatment modality was radiotherapy began that treatment within 31 days was 97.5%

A7 **62-day waits for all cancers**

In 2013-14, the percentage of patients who received a first treatment for cancer within 62 days following an urgent GP referral for suspected cancer was 85.8%

In 2013-14, the percentage of patients who received a first treatment for cancer within 62 days following referral from a NHS cancer screening service was 94.7%

In 2013-14, the percentage of patients who received a first treatment for cancer within 62 days following a consultant decision to upgrade their priority was 91.8%

## Annex B Glossary of terms

- B1 These are the definitions used for the purposes of compiling these statistics on waiting times for suspected and diagnosed cancer patients:
- B2 **Admitted Care**  
A patient receives treatment following an admission. The admission will be either a 'day-case' admission, where the time in hospital does not involve an overnight stay or an 'ordinary admission'.
- B3 **All Cancers**  
The 'all cancer' line in these statistics is the sum of all the types of cancer (see below) covered by the data collection.
- B4 **All Care**  
All patients receiving treatment, either within the 'Admitted Care' or 'Non-Admitted Care' categories.
- B5 **Anti-Cancer Drug Regimen**  
This is treating a patient's cancer with curative intent. Types of anti-cancer drug treatment modality included within this wider classification include, cyto-toxic chemotherapy, immunotherapy, hormone therapy and other forms of drug treatment not identified in the previous three categories.
- B6 **Cancer**  
Within the statistics presented in this report, cancer is defined using the International Classification of Diseases 10<sup>th</sup> revision (ICD-10). This is a coded classification of disease. The code categories identified as being cancer for the purpose of monitoring waiting times for suspected and diagnosed cancer patients are C00 to C97 and D05.
- B7 **Cancer referral to treatment period start date**  
This is the date upon which the clock starts for monitoring of a cancer referral to treatment period. This is start point for the calculation of a patient waiting time for the two-week wait and the 62-day (two month) standards.
- B8 **Cancer treatment period start date**  
This is the date upon which the clock starts for the 31-day first and subsequent treatment standards. It is the date the patient is informed of their diagnosis *and* agrees their care plan.
- For subsequent treatment events, if there is no new decision to treat, i.e. the care plan was agreed prior to the first treatment taking place, this date is taken as the Earliest Clinically Appropriate Date (ECAD), i.e. the earliest date it is clinically suitable for the patient to receive their second or subsequent treatment.
- B9 **Clinical Commissioning Group**  
For the data published in this report which includes information to 2013-14, a clinical commission group (CCG) is a type of NHS trust that managed the provision of primary care services in a specific area for a specific population, and commissions secondary care (hospital) services as required to meet the healthy needs of that population.



## Waiting Times for Suspected and Diagnosed Cancer Patients 2013-14 Annual Report

### B10 **Commissioner Based**

Commissioner based statistics are where data are presented in a manner that only includes those patients whose care is commissioned by the English NHS. In the case of statistics covering waiting times for cancer service these statistics are derived from the patient records returned by NHS providers by identifying those patients registered with the English NHS. These statistics exclude patients from the other administrations within the UK.

### B11 **Consultant Upgrade**

The consultant responsible for the care of the patient (or an authorised member of the consultant team as defined by local policy) decided that the patient should be upgraded onto an urgent cancer pathway.

### B12 **General Practitioner (GP)**

A GP is a healthcare professional delivering primary health services, they may be either a General Medical Practitioner (GMP) or a General Dental Practitioner (GDP). In the context of cancer waiting times both a GMP and GDP can initiate a two-week wait period with an urgent referral for suspected cancer.

### B13 **Modality**

A treatment modality is the defined type of anti-cancer treatment a patient will be receiving. These can either be active anti-cancer treatments (for example teletherapy (beam radiation), surgery and cyto-toxic chemotherapy) or non-active (for example specialist palliative care or active monitoring)

### B14 **NHS Cancer Screening Service**

A service providing population based screening for breast, cervical and bowel cancers

### B15 **Non-Admitted Care**

A patient receives treatment following in a non-admitted setting. The treatment will be either in an outpatient clinic, a community setting or another non-admitted environment.

### B16 **One month**

For the purpose of calculating performance in relation to waiting times for diagnosed cancer patients 'one month' is always taken to be 31 calendar days.

### B17 **Provider**

This is the organisation (NHS Trust, NHS Foundation Trust, Independent Healthcare Organisation or Clinical Commissioning Group) commissioned to provide cancer services by a patients local Clinical Commissioning Group.

### B18 **Provider Based**

Provider based statistics are where data are presented in a manner that identifies individual care providers. Patients are free to travel to any provider within the English NHS where their local CCG has commissioned services. Statistics of this type have no geographical basis and may include patients entering the English NHS from other administrative areas, e.g. Wales.

## Waiting Times for Suspected and Diagnosed Cancer Patients 2013-14 Annual Report

### B19 **Rarer Cancers**

Rarer cancers are those with smaller numbers of cases. Within the publications of waiting times, statistics for suspected and diagnosed cancer patients 'rarer' cancers are defined as testicular cancer, acute leukaemia and children's cancers.

### B20 **Referral From and NHS Screening Service**

Patients with suspected cancer identified by an NHS Cancer Screening Service will be referred to an appropriate specialist for further investigation. The receipt of this referral is considered a cancer referral to treatment period start date for the monitored 62-day period between referral from an NHS screening service and first definitive treatment.

### B21 **Specialist**

The two-week wait ends at the point a patient is first seen by a specialist. A specialist is defined as: A registered healthcare professional working as a consultant or as part of a consultant led team, who specialises in the area of professional practice that is most appropriate for the diagnosis and treatment of the type of suspected cancer in question.

### B22 **Treatment start date**

The date upon which the patients begins their first definitive or subsequent treatment for cancer. This is taken as the date of the treatment or the date of admission if the patient is admitted for surgery. This stops the waiting time clock.

### B23 **Two months**

For the purpose of calculating performance in relation to waiting times for diagnosed cancer patients 'two months' is always taken to be 62 calendar days.

### B24 **Two weeks**

For the purpose of calculating performance in relation to waiting times for suspected cancer patients 'two weeks' is always taken to be 14 calendar days, with the date of receipt of referral being 'day zero'.

### B25 **Urgent GP Referral**

The two-week wait is initiated by the receipt of an urgent GP referral for suspected cancer. Within the NHS this is sometimes called a "two-week referral" or a "fast-track referral".

### B26 **Year**

These data are presented for an NHS business year that runs 01 April to 31 March